The Mechanism of Rac1 in Regulating HCC Cell Glycolysis Which Provides Underlying Therapeutic Target for HCC Therapy

Figure 5

Antitumor effects of combination therapy of Sorafenib and the RAC1 inhibitor in HCC cells. (a). Cell viability was evaluated at 48 h after Sorafenib and EHop-016 treatment. (b). Cell cycle analysis using flow cytometry in HCC cells treated with the indicated concentration of Sorafenib, EHop-016, or combination therapy for 24 h. (c). The apoptotic rates of HCC cells treated with the indicated concentration of Sorafenib, EHop-016, or combination therapy for 24 h were measured by flow cytometry. . Statistical differences were analyzed using Student’s t-tests. Error bars represent SEM from triplicate experiments.

(a)

(b)

(c)